Market Research Logo

Pulmonary Fibrosis - Pipeline Review, H2 2015

Pulmonary Fibrosis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2015’, provides an overview of the Pulmonary Fibrosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pulmonary Fibrosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pulmonary Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Pulmonary Fibrosis Overview
Therapeutics Development
Pipeline Products for Pulmonary Fibrosis - Overview
Pipeline Products for Pulmonary Fibrosis - Comparative Analysis
Pulmonary Fibrosis - Therapeutics under Development by Companies
Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes
Pulmonary Fibrosis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Pulmonary Fibrosis - Products under Development by Companies
Pulmonary Fibrosis - Products under Investigation by Universities/Institutes
Pulmonary Fibrosis - Companies Involved in Therapeutics Development
AdAlta Pty Ltd.
Advinus Therapeutics Ltd.
Aeolus Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc.
AnaMar AB
Angion Biomedica Corp.
aTyr Pharma, Inc.
Biogen, Inc.
Bioneer Corporation
BiOrion Technologies B.V.
Bristol-Myers Squibb Company
Carolus Therapeutics, Inc.
Celgene Corporation
Chong Kun Dang Pharmaceutical Corp.
Clanotech AB
Compugen Ltd.
Cynata Therapeutics Limited
Digna Biotech, S.L.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
FibroGen, Inc.
Galapagos NV
Galectin Therapeutics, Inc.
GenKyoTex S.A.
Gilead Sciences, Inc.
HanAll Biopharma Co., Ltd.
HEC Pharm Co., Ltd.
Histocell S.L.
iBio, Inc.
IMMD Inc.
ImmuneWorks, LLC
Inventiva SAS
Isarna Therapeutics GmbH
Kadmon Corporation, LLC
Kasiak Research Private Limited
KineMed, Inc.
Kyorin Pharmaceutical Co., Ltd.
Lpath, Inc.
LTT Bio-Pharma Co., Ltd.
MedImmune, LLC
miRagen Therapeutics, Inc.
Moerae Matrix, Inc.
MorphoSys AG
MSM Protein Technologies, Inc.
NicOx S.A.
Pacific Therapeutics Ltd.
Pharmaxis Limited
Pharmicell Co., Ltd.
Pluristem Therapeutics Inc.
Progenra, Inc.
Promedior, Inc.
ProMetic Life Sciences Inc.
Pulmatrix, Inc.
RedHill Biopharma Ltd.
Respira Therapeutics, Inc.
RestorGenex Corporation
Rhizen Pharmaceuticals SA
Ribomic Inc.
Sanofi
SciFluor Life Sciences, LLC
TaiwanJ Pharmaceuticals Co., Ltd.
Teva Pharmaceutical Industries Limited
Therabron Therapeutics, Inc.
Vericel Corporation
Yuhan Corporation
Pulmonary Fibrosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(pentoxifylline + acetylcysteine) - Drug Profile
ABC-294640 - Drug Profile
AEOL-10150 - Drug Profile
AF-219 - Drug Profile
Altepan - Drug Profile
AM-0010 - Drug Profile
AMAP-102 - Drug Profile
Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile
Antisense RNAi Oligonucleotide for COPD and IPF - Drug Profile
Antisense RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis - Drug Profile
BB-3 - Drug Profile
BG-00011 - Drug Profile
BMS-986020 - Drug Profile
BOT-191 - Drug Profile
CC-539 - Drug Profile
CC-90001 - Drug Profile
CG-1011 - Drug Profile
CGEN-25009 - Drug Profile
CKD-942 - Drug Profile
CLT-28643 - Drug Profile
CMYJH-01 - Drug Profile
CT-140 - Drug Profile
CT-2009 - Drug Profile
D-9030 - Drug Profile
DB-02901 - Drug Profile
disitertide - Drug Profile
Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile
Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile
FG-3019 - Drug Profile
GC-4419 - Drug Profile
GKT-831 - Drug Profile
GLPG-1690 - Drug Profile
GRMD-02 - Drug Profile
HC-016 - Drug Profile
HEC-00000585 - Drug Profile
HL-156FIB - Drug Profile
HR-017 - Drug Profile
IBIOCFB-03 - Drug Profile
ICG-001 - Drug Profile
IMD-1041 - Drug Profile
ISTH-0047 - Drug Profile
ITMN-10534 - Drug Profile
ITMN-14440 - Drug Profile
ITMN-30162 - Drug Profile
IVA-337 - Drug Profile
IW-001 - Drug Profile
ixmyelocel-T - Drug Profile
JKB-117 - Drug Profile
JKB-119 - Drug Profile
KBP-7018 - Drug Profile
KD-025 - Drug Profile
lebrikizumab - Drug Profile
Lpathomab - Drug Profile
LT-0011 - Drug Profile
LTI-03 - Drug Profile
Lungcellgram - Drug Profile
LY-2109761 - Drug Profile
MGN-4220 - Drug Profile
MMI-0100 - Drug Profile
MOR-107 - Drug Profile
MSM-735 - Drug Profile
NAS-911 - Drug Profile
NCX-466 - Drug Profile
Neumomir - Drug Profile
noscapine - Drug Profile
Oligonucleotides for Respiratory and Oncology - Drug Profile
OLX-201 - Drug Profile
P-007 - Drug Profile
P-013 - Drug Profile
P-17 - Drug Profile
PB-01 - Drug Profile
PBF-1129 - Drug Profile
PBI-4050 - Drug Profile
pirfenidone - Drug Profile
PLX-PAD - Drug Profile
PNQ-103 - Drug Profile
PRI-724 - Drug Profile
PRM-151 - Drug Profile
PUR-1500 - Drug Profile
PXS-4820 - Drug Profile
PXS-5033A - Drug Profile
Q-122 - Drug Profile
RBM-005 - Drug Profile
RBM-006 - Drug Profile
Recombinant Enzyme to Replace MMP-9 for Liver Fibrosis and Pulmonary Fibrosis - Drug Profile
Recombinant Peptides for Fibrosis - Drug Profile
Recombinant Protein for Inflammation and Pulmonary Fibrosis - Drug Profile
Recombinant Protein for Lung Inflammation and Fibrosis - Drug Profile
Recombinant Protein to Inhibit BMP-1 like Proteinases for Pulmonary Fibrosis - Drug Profile
Refacell-IPF - Drug Profile
RES-529 - Drug Profile
RP-6503 - Drug Profile
RT-234 - Drug Profile
SAR-156597 - Drug Profile
SD-560 - Drug Profile
simtuzumab - Drug Profile
Small Molecule for Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecule to Antagonize 5-HT2 Receptor for Inflammatory Pain and Pulmonary Fibrosis - Drug Profile
Small Molecule to Inhibit MAPK for Pulmonary Fibrosis - Drug Profile
Small Molecules for COPD and IPF - Drug Profile
Small Molecules for Fibrosis - Drug Profile
Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis - Drug Profile
Small Molecules to Inhibit LOXL2 for Oncology and Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecules to Inhibit PTPN13 for Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis - Drug Profile
SPL-334 - Drug Profile
Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile
Stem Cell Therapy for Idiopathic Pulmonary Fibrosis - Drug Profile
Stem Cell Therapy for Lung Fibrosis - Drug Profile
Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury - Drug Profile
TD-139 - Drug Profile
tipelukast - Drug Profile
tralokinumab - Drug Profile
YH-siRNA1 - Drug Profile
ZL-2101 - Drug Profile
ZL-2102 - Drug Profile
Pulmonary Fibrosis - Recent Pipeline Updates
Pulmonary Fibrosis - Dormant Projects
Pulmonary Fibrosis - Discontinued Products
Pulmonary Fibrosis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Pulmonary Fibrosis, H2 2015
Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Investigation by Universities/Institutes, H2 2015
Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H2 2015
Pulmonary Fibrosis - Pipeline by Advinus Therapeutics Ltd., H2 2015
Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by Afferent Pharmaceuticals, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by AnaMar AB, H2 2015
Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp., H2 2015
Pulmonary Fibrosis - Pipeline by aTyr Pharma, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by Biogen, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H2 2015
Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2015
Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2015
Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by Celgene Corporation, H2 2015
Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
Pulmonary Fibrosis - Pipeline by Clanotech AB, H2 2015
Pulmonary Fibrosis - Pipeline by Compugen Ltd., H2 2015
Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Limited, H2 2015
Pulmonary Fibrosis - Pipeline by Digna Biotech, S.L., H2 2015
Pulmonary Fibrosis - Pipeline by Eli Lilly and Company, H2 2015
Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by Galapagos NV, H2 2015
Pulmonary Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H2 2015
Pulmonary Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Pulmonary Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2015
Pulmonary Fibrosis - Pipeline by Histocell S.L., H2 2015
Pulmonary Fibrosis - Pipeline by iBio, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by IMMD Inc., H2 2015
Pulmonary Fibrosis - Pipeline by ImmuneWorks, LLC, H2 2015
Pulmonary Fibrosis - Pipeline by Inventiva SAS, H2 2015
Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2015
Pulmonary Fibrosis - Pipeline by Kadmon Corporation, LLC, H2 2015
Pulmonary Fibrosis - Pipeline by Kasiak Research Private Limited, H2 2015
Pulmonary Fibrosis - Pipeline by KineMed, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
Pulmonary Fibrosis - Pipeline by Lpath, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015
Pulmonary Fibrosis - Pipeline by MedImmune, LLC, H2 2015
Pulmonary Fibrosis - Pipeline by miRagen Therapeutics, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by MorphoSys AG, H2 2015
Pulmonary Fibrosis - Pipeline by MSM Protein Technologies, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by NicOx S.A., H2 2015
Pulmonary Fibrosis - Pipeline by Pacific Therapeutics Ltd., H2 2015
Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H2 2015
Pulmonary Fibrosis - Pipeline by Pharmicell Co., Ltd., H2 2015
Pulmonary Fibrosis - Pipeline by Pluristem Therapeutics Inc., H2 2015
Pulmonary Fibrosis - Pipeline by Progenra, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by Promedior, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2015
Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by RedHill Biopharma Ltd., H2 2015
Pulmonary Fibrosis - Pipeline by Respira Therapeutics, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by RestorGenex Corporation, H2 2015
Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals SA, H2 2015
Pulmonary Fibrosis - Pipeline by Ribomic Inc., H2 2015
Pulmonary Fibrosis - Pipeline by Sanofi, H2 2015
Pulmonary Fibrosis - Pipeline by SciFluor Life Sciences, LLC, H2 2015
Pulmonary Fibrosis - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2015
Pulmonary Fibrosis - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Pulmonary Fibrosis - Pipeline by Therabron Therapeutics, Inc., H2 2015
Pulmonary Fibrosis - Pipeline by Vericel Corporation, H2 2015
Pulmonary Fibrosis - Pipeline by Yuhan Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Pulmonary Fibrosis Therapeutics - Recent Pipeline Updates, H2 2015
Pulmonary Fibrosis - Dormant Projects, H2 2015
Pulmonary Fibrosis - Dormant Projects (Contd..1), H2 2015
Pulmonary Fibrosis - Dormant Projects (Contd..2), H2 2015
Pulmonary Fibrosis - Dormant Projects (Contd..3), H2 2015
Pulmonary Fibrosis - Dormant Projects (Contd..4), H2 2015
Pulmonary Fibrosis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Pulmonary Fibrosis, H2 2015
Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report